Table of Contents
Introduction
When treating blood cancer in older patients, the clinician must balance treatment efficacy with safety risk. Age-related physiological reserve decline, presence of multiple comorbid conditions, and an increased sensitivity to treatment-related toxicity means that many patients older than 75 years may have limited tolerance for conventional chemotherapy. Therefore, alternative therapies with more targeted mechanisms and potentially improved tolerability, such as zanubrutinib, are often considered.
Recently, BTK inhibitors have been undergoing significant changes with zanubrutinib representing a newer-generation BTK inhibitor evaluated in clinical practice. Zanubrutinib has been evaluated in clinical studies for tolerability and efficacy in certain B‑cell malignancies and approved for the treatment of certain B‑cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphomas (MCL), and Waldenstrom’s macroglobulinemia (WM), based on regulatory indications.
Mechanism of Action and Clinical Value
Zanubrutinib is one of the newer generation BTK inhibitors that has the ability to target and inhibit the biochemistry of the B-cell receptor signaling pathway, which is essential for the survival of malignant B cells. The mechanism of BTK inhibitors acts at the intracellular level, and as such, BTK inhibitors are generally associated with a different tolerability profile compared with chemoimmunotherapy, although adverse events may still occur.
Because zanubrutinib has a more favorable pharmacokinetic profile than its predecessors, the level of BTK/SFK inhibition is maintained at the appropriate therapeutic level for a longer period of time, thereby improving the pharmacological action of zanubrutinib. zanubrutinib has demonstrated higher selectivity for BTK in clinical studies and, as such, reduced off-target effects may contribute to an improved tolerability profile.
Why Elderly Patients Need a Tailored Approach
When formulating treatment plans for patients 75 years of age and older, it is clear that the treatment goals and outcomes of the treatment are very different for patients of this age. With aging comes a decline in organ function and a decrease in resilience to disease, which are important factors that must be considered when developing an individualized treatment strategy.
Concerns In Treating Older Patients
- Older individuals’ liver and kidney organs do not work as effectively as those in younger patients. This makes drug clearance slower.
- Heart disease is more likely in older individuals.
- The immune system loses effectiveness as people age, which allows infections to occur more easily.
- Polypharmacy may increase the risk of drug–drug interactions.
- Patients often find it difficult to stick to the prescribed treatments.
The combination of the above factors highlights the importance of careful evaluation and monitoring prior to initiating zanubrutinib treatment.
The Clinical Benefit of zanubrutinib for Older Patients
The effects of using zanubrutinib as a treatment have been evaluated in multiple clinical trials and studies.
Key clinical observations from studies of zanubrutinib include:
- Atrial fibrillation happens less frequently than when using older BTK medications.
- Lower rates of certain adverse events, such as bleeding, have been reported compared with earlier BTK inhibitors.
- There is a high overall responsiveness across the wide range of B-cell malignancy.
- In cases of relapse or refractory disease, clinical studies have reported sustained responses in some patients.
- Patients can have zanubrutinib prescribed with a flexible dosage to increase compliance.
These characteristics may be considered by healthcare professionals when evaluating treatment options for older adults.
The Steps in Improving the Use of zanubrutinib
Careful prescribing of the medication is not the only input that can be used to improve the treatment outcome with zanubrutinib medication. Optimizing clinical outcomes depends on patient-specific factors, including comorbidities, functional status, and treatment goals. The input can be centered around the patient’s current health status and the future goals for that patient’s treatment.
1. Comprehensive Assessment of the Patient
There is a large amount of clinical work that can be done to evaluate the risks and benefits of zanubrutinib treatment and the participant’s suitability for treatment.
- Assess patients using the ECOG method to identify how much or little of their status would prevent the patient from performing the activities of daily living.
- Assess the functionality of the patient’s liver and kidney organs.
- Assess and identify any existing diseases that the individual is suffering from that are in addition to the disease that is being treated using zanubrutinib.
- Assess and identify the medications that the individual is taking to determine if any of those medications are likely to interact with the medication that is being prescribed to the patient during the course of their treatment with zanubrutinib.
- Assess and identify the patient’s level of frailty and nutrition.
Evaluation of these factors is critical to determining the overall health of the patient and how the zanubrutinib medication can be customized to that specific individual.
2. Personalized Dosing and Administration
In elderly patients, dosing strategies should be guided by tolerability rather than age alone. Treatment typically begins with a standard dosing strategy, with adjustments based on patient tolerability and clinical response.
3. Adverse Effects Monitoring
Elderly individuals may need more monitoring and evaluation, as closer monitoring is often required in older patients receiving therapy.
Although the side effects can be low level and infrequent, the side effects of the treatment can include:
- Weakness and dizziness
- Low-grade to moderate adverse events, including bruising, bleeding, upper respiratory infections
- Cytopenias
In some cases, more serious complications may occur, requiring closer monitoring, including routine blood count assessments (CBC), particularly in higher-risk patients.
Infections may be more severe in older patients, making early detection and monitoring important.
4. Drug Interactions Monitoring
Drug interactions need monitoring due to the susceptibility of the treatment to the interactions and due to the effect on the patients.
- Caution is advised when co-administering strong CYP3A inhibitors, as they may affect zanubrutinib metabolism.
- Both strong and moderate CYP3A inhibitors may require dose adjustments or closer monitoring
5. Follow Up to Patient Adherence
Elderly patients can be more easily disconnected from the treatment due to their age and cognitive level. Therefore, regular patient follow-up is important to support adherence and optimize treatment outcomes.
Practical Strategies:
- Simplifying medication schedules
- Utilizing pill organizers/remainder systems
- Including caregivers in the treatment plan
- Providing straightforward instructions
- Regular scheduling
Directly improving adherence enhances the success of zanubrutinib use.
Application in Specific Hematologic Malignancies
Zanubrutinib’s versatility in geriatric oncology stems from its strong efficacy across numerous B-cell malignancies.
Key Indications:
- Chronic lymphocytic leukemia (CLL): Efficacy in both frontline and relapsed settings.
- Mantle cell lymphoma (MCL): Indicated for patients who cannot tolerate chemotherapy.
- Waldenström macroglobulinemia (WM): Indicated for symptom control and reduction of IgM.
Consistent performance across these conditions solidifies its role in the care of older patients.
Comparison with Other BTK Inhibitors
Zanubrutinib has been evaluated in clinical studies with a differentiated safety and selectivity profile compared to other BTK inhibitors.
Key Differences:
- Higher selectivity leads to reduced off-target effects.
- Decreased cardiac toxicity compared to ibrutinib.
- Clinical studies suggest an improved tolerability profile compared with some earlier BTK inhibitors.
- Dosing flexibility and improved patient compliance.
Given the above, zanubrutinib is an option to consider for prolonged therapy in the elderly.
Challenges and Considerations
Important limitations of zanubrutinib must be acknowledged and considered prior to its prescription.
Potential Problems:
- Risk of resistance development over time
- Frequent monitoring and follow-up may be required
- High cost and low availability in some areas of the world
- Limited long-term safety data are available in very elderly populations
These considerations should be evaluated when incorporating zanubrutinib into clinical practice.
Future Perspectives
There is a lot of potential with zanubrutinib therapy. Ongoing research for the use of this treatment for combination therapy and therapy for earlier treatment lines looks promising. The future of therapy for elderly patients will keep getting better as personalized medicine continues improving.
Emerging Trends:
- Combining therapy with other types of targeted agents
- Using this therapy in the first lines of treatment
- Focusing more on clinical trials specifically for older patients
- Creating biomarkers for more effective patient selection
These changes will keep improving the effectiveness and safety of zanubrutinib.
Conclusion
Zanubrutinib has become an additional treatment option within the BTK inhibitor class for hematologic malignancies. This is especially true for older patients. These patients need treatment options that are safer and more tolerable. The targeted mechanism of action, the safety profile, and the positive clinical outcomes support its consideration as a treatment option for this population.
The use of zanubrutinib will need to be customized for each patient based on their individual health status, comorbidities, and treatment objectives. Clinicians can enhance the likelihood of the positive outcomes while decreasing the likelihood of the negative outcomes with the correct evaluation, monitoring, and adherence strategies.
The need for effective and easy to use cancer care will continue to grow with the older population. Because of this, zanubrutinib is expected to remain an important option within evolving treatment strategies.
